Study tests if Two-Drug maintenance beats One-Drug after stem cell transplant for myeloma
NCT ID NCT05271630
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at 69 people with multiple myeloma who had a stem cell transplant. It compares those who take one maintenance drug versus two drugs (an immunomodulatory agent plus a proteasome inhibitor) to see which keeps the cancer away longer. The goal is to learn if the two-drug combo leads to better outcomes, like turning cancer markers from positive to negative.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Immunomodulatory agent and proteasome inhibitor
What this could lead to
If successful, this could help doctors choose the best maintenance therapy to keep multiple myeloma in remission longer after a stem cell transplant.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove one treatment is better. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States